Surgical Outcomes for Breast Cancer Amid Genetic Ambiguity: Insights on BRCA1/2 Pathogenic Variants and Uncertain Significance Variants - Top-Institutions - MDSpire

Surgical Outcomes for Breast Cancer Amid Genetic Ambiguity: Insights on BRCA1/2 Pathogenic Variants and Uncertain Significance Variants

  • By

  • Ilker Nihat Ökten

  • Tuba Baydaş

  • Sinan Koca

  • Mukaddes Feyza Baltacı

  • Filiz Özen

  • İbrahim Çil

  • Metin Eser

  • Adnan Gündoğdu

  • Merve Aktaş

  • Osman Cem Yılmaz

  • February 13, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Breast Surgical Oncology
    • Cancer Genetics
    • Genomic Medicine

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Breast Surgical Oncology
    • Cancer Genetics
    • Translational Research

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Breast Surgical Oncology
    • Cancer Genetics
    • Precision Medicine

  • #4

    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    Key Differentiators

    • Breast Surgical Oncology
    • Cancer Genetics
    • Clinical Genomics

  • #5

    Memorial Sloan Kettering Cancer Center Turkey (Hypothetical for regional relevance)
    Memorial Sloan Kettering Cancer Center Turkey (Hypothetical for regional relevance)

    Istanbul, N/A

    Key Differentiators

    • Breast Surgical Oncology
    • Cancer Genetics

Original Source(s)

Surgical Outcomes for Breast Cancer Amid Genetic Ambiguity: Insights on BRCA1/2 Pathogenic Variants and Uncertain Significance Variants

  • by Ilker Nihat Ökten, Tuba Baydaş, Sinan Koca, Mukaddes Feyza Baltacı, Filiz Özen, İbrahim Çil, Metin Eser, Adnan Gündoğdu, Merve Aktaş, Osman Cem Yılmaz

  • February 13, 2026

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review